adyn offers The Birth Control Test, a personalized assessment that analyzes an individual's hormone levels and genetic risk to identify the most suitable birth control options with minimal side effects. This approach addresses the high rate of discontinuation among birth control users due to adverse reactions, providing a scientifically informed pathway to effective contraceptive choices.

Aikium Inc. develops SeqR proteins, a proprietary non-antibody scaffold designed to bind to intrinsically disordered regions of proteins, specifically targeting GPCRs in oncology, auto-immune diseases, and neuro-inflammatory disorders. Their technology enables the production of nanomolar binders for challenging targets where traditional antibody and small molecule approaches have failed.

Alveo is a pre-clinical stage medical diagnostics company focused on developing novel biomarker assays for early disease detection. Their technology aims to improve diagnostic accuracy and speed, addressing the critical need for timely interventions in patient care.

Ample provides a modular battery swapping solution that enables electric vehicles to achieve a full charge in under five minutes, utilizing a lightweight infrastructure that can be deployed rapidly. This technology offers a cost-effective energy delivery method, making charging 10-20% cheaper than gasoline while accommodating any electric vehicle model without requiring redesigns.

Antheia utilizes synthetic biology to manufacture biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines, enhancing the reliability and efficiency of pharmaceutical supply chains. This approach mitigates the risks of drug shortages caused by unpredictable agricultural sources and environmental factors.

Aperiam Bio develops hyperfolding variants of proteins that significantly enhance expression, solubility, and specific activity, enabling the production of stable enzymes for various applications. Their technology addresses the instability of natural proteins in harsh conditions, ensuring over 68% activity retention in therapeutics and extending the shelf life of cosmetic ingredients.

This biotech company develops bioprinted tissue therapeutics to create functional human tissues for transplantation and regenerative medicine. By addressing the shortage of donor organs and the limitations of traditional tissue engineering, their technology aims to improve patient outcomes in disease treatment.

Aumni is an investment analytics platform that centralizes venture portfolio management by extracting and analyzing data from legal deal documents, enabling precise monitoring of capitalization, valuations, and performance metrics. The platform addresses inefficiencies in portfolio reporting and data collection, allowing venture capital firms to generate actionable insights and streamline workflows.

Axonis Therapeutics is developing first-in-class oral KCC2 potentiator drugs, specifically targeting the KCC2 protein to restore functional inhibition in the brain. This approach aims to address neurological disorders such as epilepsy and pain by enhancing inhibitory signaling within the central nervous system.

Babyscripts offers a digital maternity care platform that combines a patient‑facing mobile app, remote monitoring devices, and OB‑aligned care managers to capture real‑time clinical data and patient‑reported outcomes. The solution provides automated reminders, risk‑based alerts, and a provider dashboard to improve early detection of conditions like hypertension and streamline workflow while supporting reimbursable RPM billing.

BillionToOne utilizes proprietary Quantitative Counting Templates (QCTs™) to detect and quantify disease-related DNA fragments at single base-pair resolution from cell-free DNA. This technology enables precise prenatal screening for recessive conditions and aneuploidies, addressing the need for accurate risk assessment from a simple maternal blood draw.

The startup develops a data conversion and storage platform that encodes digital information into deoxyribonucleic acid (DNA) format, providing a long-term archival solution. This technology enables customers to economically store vast amounts of data in DNA molecules, addressing the limitations of traditional digital storage methods.

CatenaBio’s CysTyr platform enables site‑specific conjugation of two or more drug payloads to a single antibody using a stable cystine‑tyrosine (C‑Y) bond. The resulting multi‑payload ADCs support flexible drug‑to‑antibody ratios and accommodate large or complex molecules, aiming to overcome resistance and improve therapeutic index in solid‑tumor indications. The technology integrates with existing antibody manufacturing processes for pharmaceutical and biotech developers.

Convergent Genomics provides UroAmp, a urine‑based liquid biopsy that extracts cell‑free DNA and applies targeted next‑generation sequencing to detect urothelial cancer‑specific mutations and copy‑number alterations. The assay generates a quantitative minimal residual disease (MRD) report within seven days, delivering prognostic and predictive data that enable earlier therapeutic decisions and reduce dependence on invasive cystoscopy.

Curai Health provides AI-assisted, chat-based primary care that integrates medical expertise with advanced software to enhance patient access and reduce healthcare costs. The platform addresses the inefficiencies of traditional care delivery by enabling scalable, cost-optimized virtual health services for patients and healthcare organizations.

This startup provides an AI-powered co-pilot for quantitative pharmacology, designed to enhance computational modeling in drug development. Its platform leverages large language models to streamline literature workflows, offering tools for multi-source parameter extraction, table and equation extraction, plot digitization, biological mechanism exploration, and model replication.

DermBiont develops targeted small molecule therapeutics and biotherapeutics to treat skin diseases by addressing the underlying causes, such as microbiome imbalances. Their pipeline includes treatments for conditions like seborrheic keratosis, hyperpigmentation, atopic dermatitis, tinea pedis, and onychomycosis.

Evonetix is developing a desktop platform that synthesizes gene-length DNA with high accuracy and scalability using a novel approach to DNA synthesis. This technology provides researchers with rapid access to precise genetic material, addressing the limitations of current gene synthesis methods that hinder innovation in healthcare and biotechnology.

The startup develops gene editing therapeutics that target and disrupt viral genes associated with neurotrophic viruses, transforming them into safe and effective treatments. This enables healthcare providers to effectively manage diseases caused by viral infections, improving patient outcomes.

One Health Company utilizes genomic testing and AI-driven precision medicine to identify targeted therapies for canine cancer, leveraging the largest proprietary cancer dataset from over 2,100 dogs. This approach addresses the high failure rate of traditional cancer treatments by providing veterinarians with data-driven insights to optimize treatment plans for individual dogs.

Fluent Biosciences offers PIPseq™, a technology that enables single-cell RNA sequencing without complex microfluidic instrumentation, allowing for the rapid and sensitive analysis of individual cells. This approach addresses the challenges of high ambient RNA background and sequencing bias, providing researchers with a cost-effective and scalable solution for diverse applications in cancer, immunology, and neuroscience.

Foresight Diagnostics utilizes PhasED-Seq™ technology to detect circulating tumor DNA (ctDNA) from a simple blood draw, enabling the identification of minimal residual disease (MRD) across various cancer types. This ultra-sensitive platform provides actionable insights throughout the patient treatment journey, enhancing cancer drug development and patient care.

Glyphic Biotechnologies develops Protein Sequencing by Expansion (ProSE™), a novel technology for high-throughput proteome sequencing. This method achieves single-molecule sensitivity for accurate discrimination of all 20 amino acids and post-translational modifications (PTMs). The platform aims to provide unprecedented precision and scalability for advancing proteomics research and therapeutic development.

Gula provides an all-in-one platform for online food ordering management, integrating menu and order management with existing Point-of-Sale systems. The solution enhances operational efficiency and increases sales by consolidating all delivery orders into a single application, allowing businesses to focus on customer service.